SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:71d903dd-cf03-45d1-9aa4-2c0e6eecfe0e"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:71d903dd-cf03-45d1-9aa4-2c0e6eecfe0e" > Characterization of...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006394naa a2200913 4500
001oai:lup.lub.lu.se:71d903dd-cf03-45d1-9aa4-2c0e6eecfe0e
003SwePub
008180323s2018 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/71d903dd-cf03-45d1-9aa4-2c0e6eecfe0e2 URI
0247 a https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.01.0272 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Kasner, Scott E.u University of Pennsylvania4 aut
2451 0a Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial
264 1b Elsevier BV,c 2018
520 a Background: The New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) trial is a randomized phase-III trial comparing rivaroxaban versus aspirin in patients with recent ESUS. Aims: We aimed to describe the baseline characteristics of this large ESUS cohort to explore relationships among key subgroups. Methods: We enrolled 7213 patients at 459 sites in 31 countries. Prespecified subgroups for primary safety and efficacy analyses included age, sex, race, global region, stroke or transient ischemic attack prior to qualifying event, time to randomization, hypertension, and diabetes mellitus. Results: Mean age was 66.9 ± 9.8 years; 24% were under 60 years. Older patients had more hypertension, coronary disease, and cancer. Strokes in older subjects were more frequently cortical and accompanied by radiographic evidence of prior infarction. Women comprised 38% of participants and were older than men. Patients from East Asia were oldest whereas those from Latin America were youngest. Patients in the Americas more frequently were on aspirin prior to the qualifying stroke. Acute cortical infarction was more common in the United States, Canada, and Western Europe, whereas prior radiographic infarctions were most common in East Asia. Approximately forty-five percent of subjects were enrolled within 30 days of the qualifying stroke, with earliest enrollments in Asia and Eastern Europe. Conclusions: NAVIGATE-ESUS is the largest randomized trial comparing antithrombotic strategies for secondary stroke prevention in patients with ESUS. The study population encompasses a broad array of patients across multiple continents and these subgroups provide ample opportunities for future research.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng
653 a Aspirin
653 a Cerebral embolism
653 a Cryptogenic stroke
653 a Embolic Stroke of Undetermined Source (ESUS)
653 a Randomized trial
653 a Rivaroxaban
653 a Stroke
653 a Stroke prevention
7001 a Lavados, Pablou University of Chile4 aut
7001 a Sharma, Mukulu McMaster University4 aut
7001 a Wang, Yongjunu Capital University of Medical Sciences4 aut
7001 a Wang, Yilongu Capital University of Medical Sciences4 aut
7001 a Dávalos, Antoniu Hospital Universitari Germans Trias i Pujol4 aut
7001 a Shamalov, Nikolayu Pirogov Russian National Research Medical University (RNRMU)4 aut
7001 a Cunha, Luisu University Hospital of Coimbra4 aut
7001 a Lindgren, Arneu Lund University,Lunds universitet,Klinisk strokeforskning,Forskargrupper vid Lunds universitet,Clinical Stroke Research Group,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)neur-ali
7001 a Mikulik, Robertu St. Anne's University Hospital Brno4 aut
7001 a Arauz, Antoniou Instituto Nacional de Neurología y Neurocirugía4 aut
7001 a Lang, Wilfried4 aut
7001 a Czlonkowska, Annau Medical University of Warsaw4 aut
7001 a Eckstein, Jensu University Hospital Basel4 aut
7001 a Gagliardi, Rubens4 aut
7001 a Amarenco, Pierreu Hopital Bichat-Claude-Bernard AP-HP4 aut
7001 a Ameriso, Sebastián F.4 aut
7001 a Tatlisumak, Turgutu Helsinki University Central Hospital4 aut
7001 a Veltkamp, Rolandu Imperial College London4 aut
7001 a Hankey, Graeme J.u University of Western Australia, Crawley4 aut
7001 a Toni, Danilo S.u Sapienza University of Rome4 aut
7001 a Bereczki, Danielu Semmelweis University4 aut
7001 a Uchiyama, Shinichirou Sanno Hospital4 aut
7001 a Ntaios, George4 aut
7001 a Yoon, Byung Woou Seoul National University Hospital4 aut
7001 a Brouns, Raf4 aut
7001 a DeVries Basson, M. M.u Tiervlei Trial Centre4 aut
7001 a Endres, Matthiasu Charité - University Medicine Berlin4 aut
7001 a Muir, Keithu University of Glasgow4 aut
7001 a Bornstein, Natan4 aut
7001 a Ozturk, Serefnur4 aut
7001 a O'Donnell, Martinu National University of Ireland Galway4 aut
7001 a Mundl, Hardiu Bayer Pharma AG4 aut
7001 a Pater, Calin4 aut
7001 a Weitz, Jeffrey4 aut
7001 a Peacock, W. Franku Baylor College of Medicine4 aut
7001 a Swaminathan, Balakumaru Population Health Research Institute, Ontario4 aut
7001 a Kirsch, Bodou Bayer Pharma AG4 aut
7001 a Berkowitz, Scott D.u Bayer Corporation, USA4 aut
7001 a Peters, Garyu Janssen Pharmaceuticals, US4 aut
7001 a Pare, Guillaume4 aut
7001 a Themeles, Ellisonu University of Pennsylvania4 aut
7001 a Shoamanesh, Ashkan4 aut
7001 a Connolly, Stuart J.4 aut
7001 a Hart, Robert G.u University of Pennsylvania4 aut
7102 a University of Pennsylvaniab University of Chile4 org
7730 t Journal of Stroke and Cerebrovascular Diseasesd : Elsevier BVg 27:6, s. 1673-1682q 27:6<1673-1682x 1052-3057
8564 u http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2018.01.027y FULLTEXT
8564 u https://helda.helsinki.fi/bitstream/10138/302414/1/1_s2.0_S1052305718300430_main.pdf
8564 8u https://lup.lub.lu.se/record/71d903dd-cf03-45d1-9aa4-2c0e6eecfe0e
8564 8u https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.01.027

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy